A study has found that polypharmacy in patients with acute heart failure is common globally and associated with older age and multimorbidity.

The calcium-sensitizing inotrope was of no help weaning patients off venoarterial (VA) extracorporeal membrane oxygenation ...

Heart failure is a complex clinical syndrome affecting around 70 million individuals globally. It has a prevalence of 2% in ...

Case demonstrates initiation of a sodium-glucose cotransporter-2 (SGLT2) inhibitor in a patient with type 2 diabetes and heart failure. A 56-year-old man with a history of hypertension and type 2 ...

Dr Anderson is a Consultant Cardiologist at St George’s Hospital, London, Chair of the British Society for Heart Failure and ...

AMSTERDAM — For patients hospitalized for acute heart failure, initiating treatment with the SGLT2 inhibitor dapagliflozin (Farxiga, AstraZeneca) before hospital discharge was safe, it appeared to ...

Heart failure often develops subtly, with overlooked symptoms like unexplained weight gain, persistent cough when lying down, ...

Baylor College of Medicine researchers have shown that a new drug appears to stabilize patients with failing hearts without the side effects of existing therapies. The drug, tezosentan, helps increase ...

March 27 (Reuters) - A drug made by Novartis AG to treat acute heart failure should not be approved because there is insufficient evidence it improves symptoms, a panel of advisers to the U.S. Food ...

Why has a 64-year-old man become increasingly short of breath over the past 2 weeks? That's what Sandra K. Rabat, DO, of A.T. Still University School of Osteopathic Medicine in Mesa, Arizona, and ...

Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple ...